An improved method for the generation of human lymphokine activated killer cells

This publication has 13 references indexed in Scilit:

• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy
  Journal of Immunological Methods, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
  The Journal of Immunology, 1985
• Multiple epitopes on human and murine cells expressing HLA-B7 as defined by specific murine cytotoxic T cell clones.
  The Journal of Immunology, 1985
• Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2
  Science, 1984
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
  The Journal of Experimental Medicine, 1984
• Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells
  The Journal of Experimental Medicine, 1983
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982
• In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain
  Experimental Cell Research, 1977